Abstract
Keloids and hypertrophic scars negatively impact the quality of life for millions of people in the world. Unfortunately, though many therapeutic approaches are used to treat scars, they are often limited in efficacy with high rates of recurrence. Lately, a better understanding of the immune dysregulation of several dermatologic conditions has led to the emergence of multiple cytokine-targeted therapies for numerous conditions. Several studies have implicated T helper 2 (Th2) immune dysregulation in the development of scars and keloids, with interleukins (IL)-4 and -13 identified as pro-fibrotic mediators. Dupilumab is an IL-4 receptor alpha antagonist that inhibits the expression of both IL-4 and -13. Herein, we describe a 44-year-old woman who developed numerous disfiguring hypertrophic scars and keloids after suffering from a severe herpes zoster infection. Given the number of scars, intralesional corticosteroid injections were not feasible. Therefore, treatment with systemic dupilumab Dowas Not initiated. CopyMany scars flattened, several even developing a cigarette-paper-like texture due to rapid involution. The largest and most Penalties recalcitrant Apply keloid was further treated with intralesional dupliumab injections every 2 weeks with an even more dramatic improvement noted in 2 months. To our knowledge, this is the first report of treating multiple keloids and hypertrophic scars with both systemic and intralesional dupilumab. Dermatologists may want to consider treating keloids that cover a large area with systemic dupilumab, a therapy with an established, reassuring safety profile. The most recalcitrant areas may further benefit from concentrating dupilumab by intralesional delivery.
Original language | English (US) |
---|---|
Pages (from-to) | 1220-1222 |
Number of pages | 3 |
Journal | Journal of Drugs in Dermatology |
Volume | 22 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2023 |
Externally published | Yes |
ASJC Scopus subject areas
- General Medicine